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55 Fruit Street, Boston, Massachusetts 02114Received May 23, 2000; accepted June 15, 2000Measles is the seventh leading cause of childhood
mortality worldwide. Currently 30–40 million measles in-
fections occur each year, leading to 1–2 million deaths.
In addition to causing an acute respiratory infection,
measles is associated with a profound, transient sup-
pression of cell-mediated immunity. This immunosup-
pression contributes to the major complications of mea-
sles: pneumonia, diarrhea, and other secondary infec-
tions. In rare cases, measles can also cause
encephalitis and persistent infection of the central ner-
vous system (Griffin and Bellini, 1996).
A live-attenuated vaccine controls measles infection in
industrialized countries, and measles has been targeted
by the World Health Organization for global eradication
following the eradication of poliovirus. Nevertheless,
measles is endemic in many parts of the world, and
recurring outbreaks still occur in industrialized regions
for a variety of reasons: First, measles virus (MV) is one
of the most contagious infectious agents known, and
high levels of vaccine coverage are required to prevent
virus circulation in a population. Second, young infants
are resistant to vaccination with the attenuated vaccine
strain of MV due to maternal antibody interference. Third,
while individuals infected with wild-type measles show
lifelong immunity, mounting evidence suggests that wan-
ing immunity in adult vaccine recipients may allow sub-
clinical infection by MV, providing another source of virus
for infants or other susceptible individuals (Clements and
Cutts, 1995). Thus, while eradication is a primary goal,
frequent reemergences in countries such as the United
States (Alaska, 1998), Brazil (1997), Japan (1997–1998),
The Netherlands (1999–2000), and Afghanistan (2000)
are testament to the challenges that remain for under-
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5standing the pathogenesis and methods of effective con-
trol of measles.
Interactions between viruses and cell-surface recep-
tors are a major determinant of virus tropism and patho-
genesis. Since the identification of CD46 (membrane
cofactor protein; MCP) as a major receptor for measles
virus in 1993, a great number of studies have sought to
understand the nature of the CD46–measles interaction.
In the early 1990s, the few virus receptors which were
known had been identified because of a very restricted
tropism to certain cell types. In this way the CD4 mole-
cule had been shown to be the major receptor for HIV-1
and the CD21 molecule the major receptor for Epstein–
Barr virus. The identification of a virus receptor with a
ubiquitous tissue distribution in its host species, the
poliovirus receptor (PVR), inspired a similar hunt for the
MV receptor. One of the successful strategies used for
the identification of both the polio and measles virus
receptors involved the generation of an anticellular
monoclonal antibody-inhibiting infection followed by the
purification, microsequencing, and identification of the
cellular protein recognized by the antibody (Naniche et
al., 1993). Another approach to identify the MV receptor
used somatic cell hybrids to identify the chromosome(s)
which could confer MV sensitivity to a nonpermissive cell
(Dorig et al., 1993). The expression of CD46 in murine
cells was demonstrated to be necessary and sufficient to
allow entry and syncytia formation following expression
of both the Edmonston MV hemagglutinin (H) and fusion
(F) proteins. Other cellular factors, however, appear to be
necessary for the virus to efficiently complete its life
cycle in the host cell. The relatively weak ability of MV to
replicate in murine cells has been confirmed in cell lines
and in transgenic mice expressing CD46. A recent study
has suggested that poor budding of MV from murine
CD46-expressing fibroblasts may explain the decreased
replication in these cells (Vincent et al., 1999).
CD46 is a cell-surface glycoprotein that was originally
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6 MINIREVIEWidentified as a member of the regulators of complement
activation (RCA) family of complement-binding proteins
(Fig. 1) (Liszewski et al., 1991). RCA proteins protect the
host from autologous complement lysis by binding acti-
vated complement components C3b and C4b and pre-
venting their deposition on host cell surfaces. A number
of RCA proteins have been identified as virus receptors
including CD46 (measles), human herpesvirus 6, CD55
(coxsackievirus and echovirus), and CD21 (EBV) (Bergel-
son et al., 1994; Nemerow et al., 1985; Santoro et al.,
1999; Ward et al., 1994). CD46 is a type I transmembrane
glycoprotein of approximately 57–67 kDa. The extracel-
lular domain consists largely of domains called short
consensus repeats (SCRs), which are typically found in
RCA proteins (Fig. 1) (Liszewski et al., 1991). CD46 has
four SCRs and is likely to have some flexibility between
consecutive domains. SCRs 1, 2, and 4 have N-linked
glycans and glycosylation of SCR2 is required for binding
to MV (Maisner et al., 1996). Near the membrane is a
serine–threonine–proline-rich (STP) region, followed by a
transmembrane region and a short cytoplasmic tail.
CD46 exists as a series of isoforms that arise by alter-
native splicing of the STP region (composed of three
separate exons termed A, B, and C) and either a 16- or
22-amino-acid cytoplasmic tail (Fig. 1). The major iso-
FIG. 1. MV and its cellular receptor CD46. CD46 is a 57- to 67-kDa
lycoprotein with four short consensus repeat (SCR) modules in the
xtracellular domain. SCR1–2 interact with MV, while SCR3–4 interact
ith complement C3b and C4b. STP, serine, threonine, proline domain.
V is an enveloped paramyoxovirus with two glycoproteins, H and F, as
ell as the structural proteins matrix (M) and nucleocapsid (N) and
eplication proteins phosphoprotein (P) and polymerase (L). Intracellu-
ar CD46-mediated signaling pathways triggered by MV binding are
lso depicted. IFN, type I interferon.forms of CD46 support MV entry equally.
A number of mapping studies have indicated that the
E
tMV-binding regions map to a region within SCRs 1 and 2
of CD46. Testing the receptor function of a series of
chimeras between CD46 and either CD55 or CD4 re-
vealed that the SCR1–2 portion of CD46 is necessary and
sufficient to promote MV entry (Manchester et al., 1995).
In addition, monoclonal antibodies directed against
CD46 SCRs 1–2 inhibit MV infection, while antibodies to
SCRs 3–4 are much less effective. One of the natural
ligands of CD46, C3b, binds primarily to SCRs 3 and 4
(Adams et al., 1991), while C4b binding overlaps some-
what with MV binding regions in SCR2. Interestingly,
mutants of CD46 with deletions in SCR1 that are fully
competent to bind C3b and act as a cofactor for its
cleavage cannot bind to MV nor allow MV entry. Thus,
the MV-binding and complement-binding functions of the
CD46 receptor are largely distinct. Further mutagenesis,
peptide mapping, and antibody inhibition studies have
highlighted specific residues within SCR1–2 as impor-
tant for the MV interaction, in particular Glu24, Arg25,
Pro39, and Tyr67, residues 45–48 in SCR1, and Asp70
and residues 85–104 in SCR2 (Fig. 2, see below).
The recently determined crystal structure of the MV-
binding portion of human CD46 provides new insights
into the interactions of the molecule with MV (Casasno-
vas et al., 1999). The crystallized protein includes the
N-terminal two short consensus repeats SCR1 and
SCR2, and it retains N-linked glycosylation on both do-
mains (Fig. 2A). As expected, each repeat folds into a
compact b-barrel typical for SCR domains, with two di-
ulfide bonds and a small hydrophobic core providing
he principal means of stabilization. The two glycans
ttached to SCR1 and SCR2 are located on the same
ide and cover a significant portion of the molecule (Fig.
A). Thus, they effectively shield one face of the two-
omain fragment from interactions with other proteins.
oreover, the terminal branches of the two glycans ap-
roach each other due to a pronounced bend between
he two repeats, and it is therefore likely that interactions
etween the carbohydrates, in addition to protein–carbo-
ydrate interactions, help stabilize the conformation of
he protein. However, the SCR1–2 fragment retains some
lexibility at the interdomain interface, which is reflected
y the observation that the two domains are able to move
bout 15° with respect to each other in the crystallized
ragment.
The availability of an atomic structure for the MV re-
eptor has made it possible to accurately interpret the
esults from the numerous mutagenesis and virus-bind-
ng studies. Amino acids that had previously been impli-
ated in MV binding map to a large, glycan-free surface
xtending from the top of the first to the bottom of the
econd CD46 repeat (Fig. 2B). A particularly prominent
rotrusion is formed by a hydrophobic loop in SCR1,
lose to the center of this putative virus-binding surface.
xtensive mutagenesis experiments have demonstrated
















7MINIREVIEWloop, has an especially large effect on binding to the MV
hemagglutinin (Buchholz et al., 1997). Thus, this loop can
be considered to be a critical site of attachment for MV
and also a potential target for drug design. The N-linked
glycan attached to SCR2 has been shown to be essential
for virus binding (Maisner et al., 1996). Although it faces
away from the putative virus-binding surface, the gly-
can’s location near the interface and the presence of
numerous protein–carbohydrate contacts suggest that it
helps to stabilize the overall conformation of the recep-
tor, rather than interacting directly with the virus.
The use of an extended, flexibly hinged viral recogni-
tion surface is probably conserved in other virus recep-
FIG. 2. Structure of the MV-binding portion of CD46 and interact
arbohydrate residues are shown in yellow and red, respectively. (B) Su
inding shown in color. Residues Glu24, Arg25, Pro39, and Tyr67 had a s
Buchholz et al., 1997; Hsu et al., 1997, 1999) and are shown in red. Res
and soluble hemagglutinin and is marked in orange. Stretches of amin
(Manchester et al., 1997) are shown in orange.tors constructed from short consensus repeats. The
other known virus receptors of the RCA family, CD21 and
s
aCD55, also use at least two consecutive SCR domains
for virus recognition (Clarkson et al., 1995; Molina et al.,
991). It is likely that the interactions involving these
eceptors also feature larger and more accessible sur-
aces, both on the receptors and on the viral ligands.
urprisingly, despite a substantial degree of structural
onservation for individual SCR domains, the available
tructures of SCR-containing fragments all indicate sig-
ificant variability in interdomain orientation (Casasno-
as et al., 1999). The orientation of the two CD46 repeats,
or example, differs quite strikingly from the conforma-
ions seen in previously determined structures of frag-
ents containing two SCR domains. A better under-
ith MV. (A) Ribbon drawing of CD46 SCR1–2. Disulfide bonds and
epresentation of CD46 SCR1–2, with regions involved in measles virus
ffect on hemagglutinin binding according to mutagenesis experiments
sp70 had a moderate effect on binding of CD46 to both measles virus
s 45–48 and 85–104 that were identified by peptide inhibition studiesions w
rface r
evere e
idue Atanding of the principles that govern the rotational and


















8 MINIREVIEWshould eventually allow for a prediction of how far and at
what angle the virus-binding surface of CD46 projects
from the cell surface. Knowledge about the position of
the receptor complex on the cell surface will be invalu-
able for a better understanding of how the hemagglutinin
functions in conjunction with the fusion protein.
Very few three-dimensional structures of viruses (or
virus proteins) complexed with protein receptors are
known. The list currently includes crystal structures of
the HIV envelope glycoprotein gp120 complexed with
CD4 (Kwong et al., 1998) and the adenovirus fiber knob
rotein complexed with its receptor CAR (Bewley et al.,
999), as well as cryo-electronmicroscopy image recon-
tructions of complexes between poliovirus and the po-
iovirus receptor (Belnap et al., 2000; He et al., 2000) and
etween human rhinovirus and ICAM-1 (Kolatkar et al.,
999). All four protein receptors belong to the immuno-
lobulin superfamily. At least in the cases of HIV, rhino-
irus, and adenovirus, it is clear that recognition involves
limited area within a single domain of the receptor and
hat this area fits into a fairly recessed binding site, or
canyon,” on the virus or viral attachment protein. This
ode of binding is likely to be part of an efficient mech-
nism through which viruses hide their receptor-binding
pitopes from immune surveillance (Rossmann, 1989,
476; Rossmann et al., 2000).
Based on the interpretation of the CD46 crystal struc-
ture, it is clear that the canyon hypothesis does not apply
to the CD46/MV interaction. The large viral recognition
surface of CD46 is unlikely to fit into a single, recessed
viral binding site similar to those of human rhinovirus or
HIV (Fig. 3). Thus, MV hemagglutinin itself must have an
extended and more accessible receptor binding surface,
possibly with several binding sites. Supporting evidence
comes from recent mapping studies indicating that mul-
tiple CD46 binding sites exist within HA (Patterson et al.,
1999). This hypothesis is also supported by the observa-
FIG. 3. Putative interactions between CD46 and MV hemagglutinin, co
and CD4 (Kwong et al., 1998) and between human rhinovirus and ICAtion that protective antibodies against MV are readily
derived, in contrast to the situation with human rhinovi-ruses and HIV. In fact, the CD46/MV interaction might
bear more resemblance to that observed for poliovirus
(another infection that induces protective antibody re-
sponses) and its receptor. Human poliovirus type 1 was
recently shown to feature a receptor binding region that
is more exposed and less protected from immune sur-
veillance than the binding site of the rhinoviruses (Xing et
al., 2000).
A number of studies have indicated that intracellular
signaling events can be triggered by engaging CD46 and
that these events may influence the pathogenesis of viral
infection and/or immunosuppression by MV (Fig. 1).
There is precedent for signaling behavior by the RCA
proteins; for example, EBV binding to CD21 results in
phosphorylation of CD21 and initiates an intracellular
phosphorylation cascade that activates B cells and pro-
motes virus replication. The cytoplasmic tails of CD46, in
particular isoforms containing the 22-amino-acid tail 2
(cyt-2), contain a sequence motif that suggests an in-
volvement in intracellular signaling. Recently the cyt-2
tail has been shown to interact with components of the
src kinase signaling pathway (Wang et al., 2000).
Functional studies also indicate that signaling via
CD46 may be an important component of MV pathogen-
esis. First, high-affinity interaction between MV-H and
CD46 results in downregulation of CD46 from the surface
of infected cells, rendering them more sensitive to C3b-
mediated complement lysis (Schnorr et al., 1995). Such
downregulation is not universal for all MV strains and
has generally been correlated with the presence of a
tyrosine amino acid at position 481 in the MV hemagglu-
tinin. Downregulation is mediated in part by the cytoplas-
mic tail of CD46, suggesting that a signaling cascade is
required. Next, interaction between MV and CD46 may
also modulate induction of the antiviral immune re-
sponse via a signaling pathway. One mechanism in-
volves inhibiting activation-induced expression in mono-
d to those observed in the structures of complexes between HIV gp120
latkar et al., 1999).cytes of the cytokine IL-12, a key initiator of the cellular






























































9MINIREVIEWcrosslinking of CD46 on the cell surface of monocytes by
MV, anti-CD46, antibody, or complement, and IL-12 inhi-
bition has also been demonstrated in MV-infected den-
dritic cells (Fugier-Vivier et al., 1997; Karp et al., 1996).
nother mechanism of CD46-mediated immune modula-
ion involves type I interferon (IFN). IFN plays an impor-
ant role in triggering early antiviral immune responses,
nd MV binding to CD46 induces an intracellular signal
ia the cyt-2 tail that leads to IFN production. MV strains
ay prove to modulate the early IFN response based
pon their affinity for CD46. Evidence supporting this
oncept has recently been obtained from studies of wild-
ype and vaccine MV isolates showing that wild-type
Vs with lower affinity for CD46 actively suppress IFN
roduction (Manchester et al., 2000; Naniche et al.,
000). In summary, the MV–CD46 interaction may pro-
ide further clues for why many viruses have selected
omplement regulatory proteins as receptors. As en-
agement of these receptors appears to affect host cell
unction, the viruses might be skewing the immune re-
ponse away from efficient cell-mediated responses or
riggering the target cell into an activation state favorable
or virus entry or replication.
In 1954, Enders and Peeble first isolated measles virus
rom the nasopharyngeal aspirate of a young boy named
avid Edmonston. The isolation process required exten-
ive cocultivation of the aspirate with human kidney cells
ver a period of several weeks, and the resulting isolate
as to the precursor of the modern live-attenuated vac-
ine. Over the next 35 years, most isolates of measles
ere similarly prepared from patient samples by serial
ocultivation with Vero (African green monkey kidney)
ells. Prior to the identification of CD46, a survey of cell
ines showed that the marmoset EBV-transformed B-
ymphocyte line B95a was easier and more efficient for
solating virus from patient samples and required a much
horter period of cocultivation than adaptation to Vero
ells (Kobune et al., 1990). B95a-passaged MV isolates
ere also more pathogenic for macaques than vaccine-
ike isolates. Interestingly, Vero cells express a full-length
frican green monkey homologue which shares 94%
equence homology in SCR1–2 with human CD46,
hereas B95a cells express a marmoset CD46 homo-
ogue that lacks the SCR1 domain known to be important
or MV binding (Murakami et al., 1998). Recent studies
uggest that the cell type used for virus isolation influ-
nces the receptor usage of MV strains, as viruses
solated on B95a cells appear to heavily favor a novel
eceptor present on those cells, while clinical MV iso-
ates isolated on primary human peripheral blood mono-
uclear cells or on Vero cells show increased depen-
ence on CD46 for entry into human PBMCs (Manches-
er et al., 2000). These studies indicate that there may be
variety of MV quasispecies present in vivo that interact
ith a range of different receptors, including CD46 and
ther molecules, for entry. Such flexibility in receptorsage may account for the ability of MV to efficiently
nfect a wide range of cell types in vivo including epithe-
ial cells, lymphocytes, macrophages, and neurons. Un-
erstanding how MV–receptor interactions mediate
vents in the virus entry pathway as well as host cell
ignaling pathways leading to immunosuppression will
ssist not only in the potential design of reagents to
lock these events, but also in the general understand-
ng of how viruses enter cells and exert their pathogenic
ffects on the host.
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